Under a definitive merger agreement, Roche will acquire outstanding shares of Foundation's common stock for $137 per share.

The FDA will consider the companion diagnostic application alongside data for Pfizer's talazoparib in BRCA-mutated advanced breast cancer.

Using whole-genome sequencing, the researchers uncovered pathogenic variants in cancer-predisposing genes in 15 percent of patients with multiple primary tumors.

With its purchase of decision support technology maker Interactive Biosoftware, Sophia looks to extend its AI platform deeper into NGS interpretation.

With sequence data for more than 118,000 tumors profiled at Foundation Medicine, investigators tracked PDL1 amplification prevalence and possible treatment implications.

In a publication last week, researchers described efforts to improve in silico methods for investigating the pathogenicity of missense BRCA1/2 variants of unknown significance.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.

In silico molecular biology tools, electronic lab notebooks, and systems for registration,
sample management, workflow management, and request management form the
foundation of informatics for biologics R&D.

When building out their informatics, most R&D organizations evaluate these solutions
independently, by checking off a list of required features. This is a good starting point, but
what are you missing by not evaluating the platform capabilities of these solutions?

The BD Rhapsody Single-Cell Analysis System empowers and streamlines single-cell research with a complete system of tools, including reagents and analysis software, that work together to meet neuroscience experimental needs. Neuroscientists’ ability to identify and characterize individual cells in the nervous system opens the door to finding pathogenic cells, regenerative cells, and pathways that drug manufacturers can exploit for the discovery of therapeutics for neurodegenerative disease.

Highly predictive patient-derived xenograft (PDX) models can predict clinical efficacy for oncology drug candidates better than traditional cell line-derived preclinical models. This white paper describes how PDX models can be used in Mouse Clinical Trials, upending the traditional paradigm in animal studies and providing a better perspective of patient-to-patient heterogeneity.